Background: The brain bioavailability of novel small molecules developed to address
| INTRODUCTION
The definition of pharmacokinetics and pharmacodynamics is an essential step in the development of a new treatment. The vast majority of blood-brain barrier (BBB) crossing investigations is performed in ex vivo rodent models using a brain uptake index, 1 in situ brain perfusion, 2 brain/plasma ratio, 3 brain homogenate technique, 4 or autoradiography. 5 While several in vivo methods such as cerebrospinal fluid (CSF) 6, 7 or extracellular fluid (ECF) sampling 8 are available, different imaging techniques such as positron emission tomography 9 or the single-photon emission computed tomography 10 can also be used, but these imaging techniques are limited by the need for a radioactive isoform of the drug of interest.
While the CSF sampling technique is routinely used, it is limited as it only addresses the drug bioavailability in one specific compartment, most often the spinal CSF. This technique allows for estimating the unbound brain concentration of compounds rapidly penetrating the brain that cross the BBB by passive diffusion.
sampling can be used to define the pharmacologically active concentration of a drug in a specific anatomical region. 4 Microdialysis is the gold standard when it comes to sampling endogenous or exogenous compounds solubilized in ECF in a specific brain area, thanks to passive diffusion through a dialysis membrane. 12, 13 Despite its advantages, [14] [15] [16] brain microdialysis is not classically used for measuring drug bioavailability or for evaluating neurotoxic exposition. This technique is mostly performed in rodents while only few studies were conducted in non-human primates. 17, 18 The BBB structure is, however, knowingly different between rodents and primates. 19 Such differences account for instance for differential efflux transporter expression [20] [21] [22] or differential metabolism. 23, 24 Thus, the use of microdialysis in the primate brain would provide the most useful information. Here, we demonstrate the usefulness and feasibility of the approach by measuring bioavailability of carbamazepine, digoxin, oxycodone, and quinidine in the striatum, a basal ganglia subcortical structure, of normal awake macaques. 
| Surgery
All surgery was carried out under isoflurane anesthesia. Customized guide cannulas (CMA 11, Sweden) were placed bilaterally above the precentral cortex (from anterior commissure: anteroposterior +7 mm, lateral 13 mm, depth +12 mm) under stereotactic guidance, 18, [37] [38] [39] [40] using ventriculography and postoperative X-ray evaluation. Guide cannulas were permanently fixed to the skull with surgical screws and dental acrylic resin. After 1 week of recovery, microdialysis recordings commenced. 
| Microdialysis

| Sample preparation
After thawing at room temperature for 1 hour, plasma samples or dialysate samples were mixed on a vortex mixer for 15 seconds. A quantity of 20 μL of plasma or CSF was added with 100 μL of the internal standard solution (glibenclamide at 0.02 μg/mL dissolved in methanol) then vortex-mixed for 30 seconds. Samples were then centrifuged at 10 000 g for 10 minutes at room temperature and 3 μL of the supernatant aliquot was injected into the liquid chromatography coupled to mass spectrometry system.
A modified protocol was used to detect digoxin in plasma. After thawing at room temperature for 1 hour, plasma samples were Deionized water used throughout the study was purified by a Milli-Q R Academic water purification system (Merck Millipore, Billerica, MA, USA).
| Chemical information
| Sample analysis
The analysis was performed on an Agilent 6410B triple quadrupole The limit of quantification for carbamazepine, oxycodone, and quinidine was 2.5 ng/mL and was 0.25 ng/mL for digoxin. The limit of detection for all drugs was not measured.
| Pharmacokinetics analysis
The area under the plasma or brain concentration-time curve (AUC 0-24 h ) was estimated by the trapezoidal rule integration using R software version 2.13.2. 44 The half-time (t 1/2 ) was calculated using the least-squares linear regression analysis of the terminal part of the log concentration-time curves, described by the two following 
| Probes recovery
The recovery of the microdialysis probes was determined in vitro by measuring the gain in the dialysis solution for each compounds:
6.2 ± 0.1, 6.1 ± 0.1, and 3.4 ± 0.2 % (mean ± SEM) for carbamazepine, oxycodone, and quinidine, respectively (Table 2 ). For digoxine, the recovery was below 0.2 % ( Table 2 ).
| Carbamazepine
Carbamazepine showed a large plasma and ECF bioavailability correlated with the dose (Figure 1 ) and a dialysate/plasma ratio of 1.139 ± 0.075 (Table 3) . Plasma and dialysis t max were comparable (Table 3) while t 1/2 differed between both compartments, 3.6 ± 0.6 hours in plasma and shorter in dialysate with 2.3 ± 0.1 hours (Table 3 ).
| Digoxin
Digoxin showed a low plasma level and was not detected in dialysis samples (concentration was lower than 0.20 ng/mL) ( Table 3 ). The bioavailability is correlated with the dose (Table 3 ).
| Oxycodone
Oxycodone showed a low plasma level but a substantial level in dialysate ( Figure 1 ) correlated with the dose and a dialysate/plasma ratio at 3.681 ± 0.645 (Table 3) . Plasma and dialysis t 1/2 were comparable (Table 3) while t max differed between both compartments 3.0 ± 0.7 hours in plasma and shorter in dialysate with 1.8 ± 0.5 hours (Table 3) .
| Quinidine
Quinidine showed a low plasma level with a substantial level in dialysate ( Figure 1) . Interestingly, plasma and dialysate pharmacokinetics parameters were not comparable and not correlated with the dose (Table 3) . Half-time were 3.7 ± 0.6 and 0.6 ± 0.1 hours and t max were 2.0 ± 0.5 and 0.7 ± 0.1 hours in plasma and dialysis samples, respectively (Table 3) .
| DISCUSSION
We show that microdialysis in the awake normal macaque is a reliable method for the detection of small molecule bioavailability in the central nervous system. All drugs, except digoxin, were found in dialysate samples and showed a correlation to plasma levels ( Figure 1 ).
Because they were obtained in the awake monkey, and since no animals were terminated for the completion of this study, these data advance the definition of brain availability of drugs when compared to previous microdialysis studies performed in sedated rhesus monkeys. 45 Sedation indeed modifies the hemodynamic parameters, inducing changes in brain chemistry and electrophysiology. 15, 46 Although this brain pharmacokinetic model shows interesting perspectives, the study is limited for several reasons. First, we did not evaluate the plasmatic unbound fraction of drugs but used primate data from literature. [47] [48] [49] | 317 approach in the awake macaque. A larger cohort would be required for measuring brain levels of new chemical entities or neurotoxicant in future studies. Given the interindividual variability observed in this study, a minimum of six animals would be required. However, the drugs being used in this study are well-known drugs. The purpose of the study was to compare the human and macaque bioavailability, hence, the choice of well-known drugs. The power was therefore sufficient for highlighting the similarities between human patients and non-human primates.
Carbamazepine crosses the BBB by passive diffusion 32 but some influx transporter may also be involved 29 53 or from rat 54 and is comparable to our data suggesting that there is no species-related differences for this drug in BBB transport.
Digoxin was not found in dialysate samples as expected according to data suggesting digoxin enters CSF very slowly with a t max 10 hours later than the plasmatic peak and according to the low plasma level of free drug. Digoxin crosses the BBB by passive diffusion 30 but is poorly lipid-soluble and slowly enters the CSF 55 and is a substrate of Pgp. 25, 56 Moreover, it also seems digoxin crosses the BBB by active transport via organic anion-transporting polypeptide 2. 25, 34, 57 This transporter, also known as solute carrier 21A6, 58 is expressed in rodent 20, 57 but not in humans 22 or non-human primates. 21 Moreover, the total clearance and bioavailability are comparable between human and monkey 47 while total clearance was higher in rodent. 34 These data support the fact that the non-human primate model is closer to human physiology for estimating brain availability of drugs which, like digoxin, have clear species-related differences in BBB transport.
Oxycodone crosses the BBB by active absorption through organic cation transporter 33, 59 and is not a substrate of Pgp.
26
Dialysate/plasma ratio is similar between macaque and rat, 368.1 ± 64.5 % (Table 3 ) and 300%, 60 respectively, but to the best of our knowledge, no dialysis data is available for oxycodone in humans.
Interestingly, brain bioavailability shows a large variability between rodent species. 61, 62 Since the organic cation transporter involved in oxycodone transport across BBB is not clearly identified, 59 it is therefore not possible to compare its expression between species and draw conclusions about pharmacokinetics differences based on such a differential expression as for digoxin.
Quinidine has a low molecular weight (324 g/mol), high lipophilicity, and besides passive diffusion, 31 quinidine would cross the BBB by active transport through organic cation transporter, especially the organic cation/carnitine transporter. 35, 36 It is also a substrate of Pgp 27 accounting for a fast but short BBB crossing explaining why the brain/plasmatic ratio differs between techniques assessing brain quinidine bioavailability 54 and why the coefficients of determination of brain/plasmatic ratio is low in transient condition (Figure 1 ). Dialysate/plasma ratio is lower in rat, 65.3 ± 24.3% (Table 3) All dialysate concentrations are corrected by the probe recovery factors showed in Table 2 fmol/μg prot for human. 22 Pgp is the more abundant efflux transporter in rodent 22 unlike primate for whom it is adenosine triphosphate-binding cassette G2 (breast cancer resistance protein). 21, 22 Our results suggest that depending on the protein involved in the efflux transport from the brain, the non-human primate model can predict more reliably the human brain bioavailability. This in part because of the comparable efflux protein expression profiles in brain microvessels of the two species. 21, 22 Other proteins are involved in the BBB function like enzymes 64 and tight junction proteins. 65, 66 These species-specific differences in expression need to be more thoroughly investigated to make a rational choice of model of human brain pharmacokinetic. 
| CONCLUSION
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